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reproduction in any medium, provided the original author and source are credited.SUMMARYInducedpluripotent stemcells (iPSCs)provide thepotential forautologoustransplantationusingcellsderived fromapatient’sowncells.How-
ever, the immunogenicityof iPSCsor their derivativeshasbeenamatterof controversy, anduptonowtherehasbeennodirect comparisonof
autologous and allogeneic transplantation in the brains of humans or nonhuman primates. Here, using nonhuman primates, we found that
the autologous transplantation of iPSC-derived neurons elicited only a minimal immune response in the brain. In contrast, the allografts
caused an acquired immune response with the activation of microglia (IBA-1+/MHC class II+) and the infiltration of leukocytes (CD45+/
CD3+).Consequently, ahighernumberofdopaminergicneuronssurvived intheautografts.Ourresults suggest that theautologoustransplan-
tation of iPSC-derived neural cells is advantageous for minimizing the immune response in the brain compared with allogeneic grafts.INTRODUCTION
In recent studies, murine induced pluripotent stem cell
(iPSC)-derived teratomas in the subcutaneous space induced
an immune response in syngeneic mice (Zhao et al., 2011).
In contrast, syngeneic transplantation of skin and bone
marrow tissues (Araki et al., 2013) or endothelial, hepatic,
and neuronal cells (Guha et al., 2013) derived from iPSCs
showed a limited or no immune response, respectively.
These rodent studies investigated the immunogenicity of
teratomas, chimericmouse-derived tissues, or ectopic grafts,
but did not convincingly simulate the clinical situation.
Parkinson’s disease is oneof themostpromising targets for
cell therapy with pluripotent stem cells, in which differenti-
ated dopaminergic (DA) neurons are transplanted into the
putamen of a patient’s brain (Lindvall and Bjo¨rklund,
2011). Inorder toassess the immunogenicityof iPSC-derived
neural cells in a primate brain, we generated iPSCs from four
cynomolgusmonkeysanddirectlycompared theautologous
and allogeneic transplantation of iPSC-derived neural cells.
RESULTS
iPSCs Derived fromNonhuman Primates Differentiate
into DA Neurons
For the first two animals (Nos. 1 and 4), we established
iPSCs from fibroblasts derived from the oral mucosa usingStem Cellretroviral vectors (Okita et al., 2011). For the other two an-
imals (Nos. 6 and 8), we used peripheral blood mononu-
clear cells (PBMCs) with nonintegrating episomal vectors
(Okita et al., 2013). We selected the best clone from each
animal according to the following criteria: a stable embry-
onic stem cell (ESC)-like morphology of the colonies after
passaging, expression of pluripotent markers, few or no in-
tegrated transgenes (Figures 1A–1F; Figure S1 available
online), and the potential for stable neural differentiation.
A PCR analysis revealed that all of the clones with retroviral
vectors showed apparent expression of remaining trans-
genes (Figures S1C and S1D), whereas the clones with
episomal vectors never did (Figure S1F). To detect the
iPSC-derived cells in a brain, we introduced GFP (Figures
1G and 1H). The selected clones of iPSCs had the potential
to generate teratomas in the testes of a severe combined im-
munodeficiency (SCID) mouse within 12 weeks (Figures
1I–1M).
To efficiently generate DA neurons from monkey iPSCs,
we modified previously described protocols (Eiraku et al.,
2008; Chambers et al., 2012; Morizane et al., 2011). Briefly,
dissociated iPSCs were incubated in ultralow-attachment
96-well plates in medium containing inhibitors of bone
morphogenetic protein (BMP) and Activin/NODAL
signaling to initiate neural induction. To induce differenti-
ation of the cells toward midbrain DA neurons, purmorph-
amine/FGF8 and FGF2/FGF20 were added sequentiallyReports j Vol. 1 j 283–292 j October 15, 2013 j ª2013 The Authors 283
Figure 1. Characterization of Primate iPSCs and iPSC-Derived Neurons
(A–H) Phase-contrast images (A, B, and G) and immunostaining for pluripotent markers (C–F) of iPSCs (T7). GFP was detected during live
imaging (G and H) in the same field.
(I–M) Teratoma formation at 3 months after transplantation in the testes of SCID mice. H&E staining of the sections showed histological
features of the neuroepithelium (J), cartilage (K), muscle (L) and gut-like epithelium (M).
(N) The protocol used for neural differentiation.
(O) Expression analyses of neural markers and Oct4 by flow cytometry. The negative control was a cell sample stained only by secondary
antibody (PSA-NCAM) or the isotype control (TUBbIII and OCT4). The positive control for OCT4 was undifferentiated (day 0) iPSCs.
(P) qPCR for the differentiation of donor cells. The data are shown as the means ± SD (n = 4 independent experiments).
(Q) Immunostaining of primate iPSC-derived neurons on day 39.
(R) Quantification of immunocytochemical analyses for each iPSC line. Data are shown as the means ± SD (n = 3 independent experiments).
SER, serotonin, TUBbIII, b-tubulin class III. Scale bars: 200 mm in (A)–(H), 50 mm in insets of (C)–(F), 100 mm in (J)–(M) and (Q).
See also Figure S1 and Tables S2 and S3.
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pluripotent marker (OCT4) gradually decreased, whereas
the levels of neural and DA markers increased (Figures 1O284 Stem Cell Reports j Vol. 1 j 283–292 j October 15, 2013 j ª2013 The Aand 1P). The differentiated neurons expressed markers
characteristic of midbrain DA neurons (LMX1A, FOXA2,
TH, and PITX3; Figures 1Q and 1R). Besides DA neurons,uthors
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GABAergic neurons, as well as proliferating neural progen-
itors positive for KI67, were also observed as minor popula-
tions (Figures 1Q and 1R). OCT4 was not detected by
immunocytochemistry or flow cytometry in the differenti-
ation culture even from the retroviral iPSCs (Figure 1O).
Expression of Major Histocompatibility Complex
by Monkey iPSCs In Vitro
Next, we investigated the expression of major histocom-
patibility complex class I (MHC-I) in iPSC-derived neural
cells. Flow cytometry using antibodies against human
leukocyte antigen (HLA)-A, HLA-B, and HLA-C revealed
that mature neurons on days 35 and 71 expressed only a
low level of MHC-I, and that the expression was enhanced
in response to interferon gamma (IFN-g: 25 ng/ml for 48 hr;
Figure 2A). The expression level of the mRNAs was approx-
imately 1:100 comparedwith peripheral blood cells in both
fibroblast- and blood-cell-derived iPSCs, which was again
increased by exposure to IFN-g (Figure 2B). These results
suggest that donor-derived neurons could express MHC-I
when INF-g was secreted by the host brain under inflam-
matory conditions.
To ensure that the MHC-Is of the host animal and donor
cells were mismatched in the allotransplantation cases, we
performed genotyping of the expressed MHCs from the
monkeys, which were purpose-bred, second-generation
(F2), captive-born animals. As shown in Figures 2C and
2E, and Table S1, each monkey expressed different MHCs
in terms of the A and B alleles. Based on these results, we
chose the most mismatched combination for allotrans-
plantation (Figures 2D and 2E).
Autografts Elicit Only a Minimal Immune Response
in the Primate Brain
We injected the iPSC-derived neural cells (day 28) into the
original monkey as an autograft, and into the MHC-mis-
matched monkey as an allograft (Figure 2D). Each animal
received six separate injections (8.0 3 105 cells in a 4 ml
suspension per tract) in the left striatum, and was observed
for 3.5–4 months without immunosuppression. In the
brain, both brain-resident microglia and circulating
immune cells work as key players in immunological re-
sponses. Once themicroglia are activated, they develop an-
tigen-presenting activity. PK11195 selectively binds to the
translocator protein that is expressed on activated micro-
glia (Shah et al., 1994; Vowinckel et al., 1997). Therefore,
positron emission tomography (PET) studies with [11C]
PK11195 have been used to visualize brain inflammation
in patients (Debruyne et al., 2003).
In sequential PET studies, we observed increased uptake
of [11C]PK11195 in one allograft (animal No. 10) at
3 months (Figures 3A and 3B). We could not detect anyStem Cellapparent uptake in the other animals or at any other time
points (Figure S2). Intriguingly, the serum level of IFN-g
temporarily increased at 2 months after the transplant in
three animals (Figure 3C). An immunofluorescence study
conducted at 3.5–4 months showed that MHC-II+ cells
were more frequently found in allografts than in auto-
grafts, especially in the monkey with increased uptake of
[11C]PK11195 (Figure 3D, No. 10). The MHC-II staining
never overlapped with that of GFP of the donor cells (Fig-
ure 3F), whereas it generally overlapped with that of IBA1
(Figure 3G), indicating that MHC-II was expressed by
host-derived microglia. Consistently, the number and den-
sity of IBA1+ cells were higher in allografts than in auto-
grafts (Figures 3E, 3H, and S4C). An increase in the expres-
sion of MHC might trigger the recruitment of circulating
immune cells, including T cells. An immunofluorescence
study revealed that more CD45+ cells (a marker for pan-
leukocytes) accumulated in allografts compared with auto-
grafts (Figures 3I and 3J). Most of the CD45+ cells were
CD3+ T cells, and 60% of themwere CD8+ killer T cells (Fig-
ures 3K and 3L). These findings suggest that an acquired
immune response was elicited only in the allografts in
the primate brain.DA Neurons Survive in Both Types of Grafts, but
a Higher Number Are Observed in Autografts
In order to evaluate the survival of the grafted cells, we per-
formed MRI scanning and a histological analysis at 3–
4 months posttransplantation (Figure 4). Hematoxylin
and eosin (H&E) staining and immunostaining for GFP of
the brain slices demonstrated that the grafted cells survived
in both auto- and allotransplantation without immuno-
suppression (Figures 4A–4F). Furthermore, there were no
significant differences in volume between the auto- and
allografts (Figure 4K). Immunostaining for tyrosine hy-
droxylase (TH), a marker for DA neurons, revealed that a
large number of DA neurons (4,428 ± 1,130 per tract, n =
22) survived in the autografts (Figures 4G, 4H, 4L, and
4M). The surviving DA neurons coexpressed the markers
of a mesencephalic phenotype, such as FOXA2, NURR1,
and the dopamine transporter (DAT) (Figures 4N–4P).
Even in allografts without immunosuppression, the TH+
neurons survived well (2,247 ± 641 per tract, n = 22), but
the number and density were lower than in autografts (Fig-
ures 4I, 4J, 4L, and 4M). We also found a small number of
astrocytes (GFP+/GFAP+), as well as mature neurons
(GFP+/NEUN+), in vivo (Figure S4B).DISCUSSION
In this study, we induced DA neurons from monkey iPSCs
by directed differentiation in vitro, and demonstrated thatReports j Vol. 1 j 283–292 j October 15, 2013 j ª2013 The Authors 285
Figure 2. Identification of MHC Expression and Typing of Donor Cells
(A) Flow-cytometric analyses for MHC-I (HLA-A, HLA-B, and HLA-C). Incubation of the cells with IFN-g for 48 hr increased the MHC-I
expression (green).
(legend continued on next page)
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Immunogenicity of iPSC-Derived Neurons in Primatesautologous transplantation of the iPSC-derived cells eli-
cited only a minimal immune response in the nonhuman
primate brain. Previous reports have suggested that either
autologous grafts of iPSC-derived neural cells (Emborg
et al., 2013; Maria et al., 2013) or allogeneic grafts of fetal
ventral mesencephalic cells (Redmond et al., 2008) can sur-
vive in a primate brainwithout immunosuppression. None
of these studies, however, directly compared the immuno-
genicity of autologous grafts with that of allogeneic ones.
Our results clearly show differences in both immunoge-
nicity and cell survival between these two types of grafts,
and support the idea that immunosuppression is not neces-
sary for autologous transplantation of iPSC-derived neural
cells into the brain. The [11C]PK11195 PET studywas useful
for real-time visualization of this phenomenon. Further-
more, this technique can also be applied to patients in
the clinical setting, which would help to determine when
and if immunosuppressive drugs can be withdrawn.
Although we did not examine acute immune responses
or inflammation within 48 hr, it is noteworthy that the re-
sponses were observed 2 or 3 months posttransplantation.
In the case of iPSC-based transplantation, there are four
possible mechanisms that can cause inflammatory and im-
mune responses: (1) direct allorecognition of mismatched
MHC or minor antigens of the donor cells, (2) indirect al-
lorecognition through host-derived antigen-presenting
cells, (3) expression of fetal antigens due to immature
stem cells or remaining transgenes, and (4) mechanical
damage rather than MHC mismatch. Because of the low
expression level of MHC-I by the donor cells, direct allore-
cognition is unlikely to be themain cause. However, donor-
cell-derived astrocytes (Figure S4B), which can express both
MHC-I and MHC-II to recruit T cells in response to IFN-g
(Akesson et al., 2009; Chastain et al., 2011), could be
observed in the grafts. Furthermore, it takes a longer time
for astrocytes to differentiate than neurons. Therefore,
although there was no apparent expression of either
MHC-I or MHC-II by the grafted GFP+ cells, donor-derived
astrocytes may have contributed to the direct reaction in
the late stage. Considering the high expression level of
MHC-II by host-derived microglia in the allografts (Figures
3D–3G), indirect allorecognition seems to have played a
major role in the present study. This requires the internal-
ization and processing of the alloantigens, which are(B) Temporal MHC-I expression analysis of monkey iPSCs by qPCR. The
blood iPSCs) different experiments. Data are shown as the means ± S
(C and E) Monkey MHC-I (Mafa) allele sequences detected by next-gen
The colored letters indicate a comparatively high expression level of t
background indicates the MHC-A allele, and the others indicate the M
(D) Combinations of donor cells and recipient animals. Episomal v.,
starting the differentiation of donor cells; Retro v., established with
See also Figure S4D and Tables S1–S3.
Stem Cellthen recognized in peptidic form bound to recipient
MHC-II molecules, possibly accounting for the late onset
of the immune response.
Autografts derived from iPSCs generated by retroviral
vectors resulted in the accumulation of larger numbers of
IBA1+ and CD45+ cells compared with those generated us-
ing episomal vectors, probably due to the residual expres-
sion of the transgenes (Figure S3). This indicates that resid-
ual transgenes can be immunogenic, and that it is therefore
critical to use integration-free iPSCs. Mechanical damage
caused by needle trauma can also activate host astrocytes
andmicroglia to secrete proinflammatory cytokines, which
recruit leukocytes. Consistently, we found IBA1+ cells along
the needle tract in the animals that received control injec-
tions (Figures 3E and S4C), but this was limited to a small
area and not likely to play a major role.
Another important finding is that, in spite of the im-
mune responses mounted by the host brain, a substantial
number of TH+ cells survived in the allografts. This is
consistent with previous clinical reports of human fetal
cell transplantation. Postmortem analyses of the patients
revealed robust survival of DA neurons in spite of the fact
that numerous immune cells were present around the graft
(Kordower et al., 1997). In two double-blind clinical trials,
immunosuppressive drugs were never used (Freed et al.,
2001) or were withdrawn after 6 months (Olanow et al.,
2003). In these cases, the cells from multiple fetuses were
used without HLA matching, but more than 50,000 TH+
cells had survived after several years. Our quantitative
PCR (qPCR) study in vitro showed that the expression of
MHC-I increased in response to IFN-g, but the expression
level was still 1/10 that of untreated monkey peripheral
blood cells (Figure 2B). The in vivo studies revealed that
the serum level of IFN-g increased at 2 months, and
CD45+ cells (including CD8+ cells) accumulated in the allo-
grafts 3.5–4 months after the transplant. On the other
hand, the levels of INF-g in the cerebrospinal fluid (CSF)
and the levels of tumor necrosis factor a (TNF-a) in both
the serum and CSF were below the limit of detection by
ELISA (data not shown). An immunofluorescence study
did not reveal any apparent expression of MHC-I by the
grafted cells (Figure S4A). Therefore, it is possible that the
immune response in the primate brain was not strong
enough to reject all of the donor cells. These findingsdata were obtained from three (n = 3 for fibro iPSCs) or five (n = 5 for
D.
eration sequencing (C) and cluster analysis of the monkey MHCs (E).
he MHC-I allele, comprising >10% of cDNA sequence reads. The gray
HC-B allele.
established with episomal vectors; P, passage number just before
retrovirus vectors.
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Immunogenicity of iPSC-Derived Neurons in Primatesclosely correlate with the results of previous murine exper-
iments (Hudson et al., 1994; Shinoda et al., 1995). To apply
our findings to a more clinically relevant setting, we inves-
tigated the expression of HLA-I during neural differentia-
tion of human ESCs (hESCs) and iPSCs by qPCR (Fig-
ure S4D). The expression level was 1/100 compared with
that of human peripheral blood cells in both hESCs and
iPSCs, and it was similarly elevated in response to IFN-g.
It is difficult to precisely compare immunogenicity in
monkeys with that in humans, but the low expression
level of MHC-I by the donor cells may account for the
mild rejection in both monkey and human neural
transplantation.
Our results indicate that autologous transplantation is
beneficial in terms of the immune response and cell sur-
vival. However, this strategy is associated with higher
costs and labor. An alternative method is allogeneic trans-
plantation using HLA-matched iPSC stocks (Okita et al.,
2011; Nakatsuji et al., 2008; Deleidi et al., 2011). There-
fore, as a next step, it is critical to determine whether
autografts have advantages over HLA-matched allografts
and HLA-mismatched allografts with immunosuppres-
sion. To answer this question, it will be necessary to
establish iPSCs from MHC-homozygous monkeys and
transplant the iPSC-derived cells into monkeys with the
identical MHC haplotype. The precise influence of HLA
mismatch therefore needs to be explored in such future
studies.EXPERIMENTAL PROCEDURES
Nonhuman Primates
Eight purpose-bred male cynomolgus monkeys (Macaca fascicula-
ris) were used for iPSC generation and transplantation. The animal
experimentswere performed in accordancewith theGuidelines for
Animal Experiments of Kyoto University, the Institutional Animal
Care and Use Committee of Kobe Institute in RIKEN, and the
Guide for the Care and Use of Laboratory Animals of the Institute
of Laboratory Animal Resources (Washington, DC, USA). See also
Supplemental Experimental Procedures.Figure 3. Immune Responses following Autologous or Allogeneic
(A and B) [11C]PK11195 PET study of the allografts in animal No. 10,
The illustration in (A) shows the method used for cell injection.
(C) Temporal changes in the serum level of IFN-g. Bottom: a two-way
n = 4 animals, *p < 0.05. Data are shown as the means ± SEM.
(D–H) Histological analyses of the host-resident microglia. The image
for coronal sections (D). The arrowheads in (A) and (D) indicate the
(I–L) Histological analyses of infiltrating leukocytes.
Scale bars: 1 cm (A), 2 mm (D), 100 mm (E and I), and 20 mm (F, G, K,
tracts). Ratio paired t tests were performed for the auto- and allo-tract
(J, upper), *p = 0.0122 (J, lower). All of the PET, MRI, and histologi
See also Figures S2–S4 and Table S3.
Stem CellGeneration and Neural Differentiation of iPSCs
Fibroblasts from the oral mucosa were transfected retrovirally with
five transgenes (OCT3/4, SOX2, KLF4, L-MYC, and LIN28) (Okita
et al., 2011). PBMCs were transfected with a combination of
plasmid vectors (OCT3/4, SOX2, KLF4, L-MYC, LIN28, shRNA for
TP53, and EBNA1) as described previously (Okita et al., 2013).
The primate iPSCs were maintained on mouse embryonic fibro-
blast feeders treated with mitomycin-C (Sigma-Aldrich). They
were differentiated into DA neurons through the SFEBq method
(Eiraku et al., 2008) with dual SMAD inhibitors (Chambers et al.,
2012;Morizane et al., 2011; Figure 1N). The cells were transplanted
on day 28 of differentiation. For in vitro analysis, the cells were
dissociated with Accumax (Innovative Cell Technologies) on day
28 and cultured on eight-well glass chamber slides coated with
poly-l-ornithine and laminin for an additional 11 days (for a total
of 39 days).
Genotyping of MHC
MHC genotypes were assigned by comparing the sequences with
knownMHC allele sequences released from the Immuno Polymor-
phism Database (http://www.ebi.ac.uk/ipd/index.html). See also
Supplemental Experimental Procedures.
Immunostaining and Histological Analyses
For in vivo studies, the fixed frozen brains were sliced at 40 mm
thickness and immunologically stained via the free-floating
method. The primary antibodies used are listed in Table S3. See
also Supplemental Experimental Procedures.
MRI and PET Studies
PET scans with [11C]PK11195 were performed with the use of an
animal PET scanner (microPET Focus220; Siemens Medical Solu-
tions) to identify the activation of microglia. High-resolution T1-
weighted and T2-weighted images were obtained using a 3T MRI
scanner (MAGNETOMVerio; SiemensAG) to identify the injection
site of grafts in the postero-dorsal striatum and to evaluate graft
survival. See also Supplemental Experimental Procedures.
Transplantation
Floating aggregates (day 28) were harvested and dissociated into
small clumps of 20–30 cells with Accumax. The cells were sus-
pended in the last culture medium (Figure 1N), which wasTransplantation
in which the highest immune response was observed histologically.
ANOVA was performed with Bonferroni’s multiple-comparisons test;
of H&E staining of animal No. 8 is shown as an anatomical reference
direction of the cell injections.
and L). Quantitative data are presented as the means ± SEM (n = 22
s. ***p = 0.0003 (H, upper), **p = 0.0015 (H, lower), **p = 0.0035
cal images show coronal sections.
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Figure 4. Graft Survival in a Primate Brain
(A–P) Histological analyses of a brain section with H&E staining, and the immunohistochemical findings.
(K) Quantitative analyses of the graft volume.
(L and M) Survival of TH+ neurons in the grafts.
(N and O) The TH+ neurons expressed markers of the midbrain phenotype: Foxa2 (N) and Nurr1 (O).
(P) The DAT was also positively stained.
(legend continued on next page)
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cAMP, glial-cell-line-derived neurotrophic factor, and brain-
derived neurotrophic factor. We also added a ROCK inhibitor,
Y27632, to increase the survival of the donor cells. The suspension
was prepared at a concentration of 23 105 cells/ml, and 4 ml of the
suspension was injected through a 22-gauge needle with a Hamil-
ton syringe. We made six (two coronal 3 three sagittal) tracts of
injection in one side of the putamen. In total, 4.8 3 106 cells per
animal (8.0 3 105 cells/tract 3 6 tracts) were injected into one
side of the putamen according to the coordinate decided by the
MRI image of each monkey. The same volume of the culture me-
diumwas injected to the contralateral side as control. No immuno-
suppressant was used. Under deep anesthesia, the animals were
sacrificed and perfused transcardially with 4% paraformaldehyde
after 3.5–4 months of observation.Statistics
The data were expressed as the mean ± SD or mean ± SEM, and dif-
ferences were tested by commercially available software Prism 6
(GraphPad). With regard to the histological data for the auto-
and allo-tracts, after confirming normal distribution, we proceeded
to perform statistical analyses with ratio paired t tests. Some tracts
were omitted from the assessment because of technical problems;
p values < 0.05 were considered to be significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and three tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2013.08.
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